BSD Medical rises on China deals. The Medicines Company surges on Angiomexnt rumors. Print E-mail
By BioMedReports.com Staff   
Thursday, 09 September 2010 17:28

Below is a list of the companies that made news in the healthcare sector on Thursday, September 09, 2010.

Shares of The Medicines Company (NASDAQ:MDCO) surged in late trading today as rumors swirled regarding the court case surrounding the companies lead drug, Angiomexnt. On August 6th, the U.S. Patent and Trademark Office granted a one-year interim extension of the term of the principal U.S. patent that covers Angiomax, until August 13, 2011. On heavy volume MDCO shares rallied more than 12% or $1.44 to $13.17. In extended trading Thursday, shares rose another 11 cents.

BSD Medical Corporation (NASDAQ: BSDM) announced today that Dalian Orientech Co. Ltd, the Company’s exclusive China distributor, has ordered two BSD-2000 Hyperthermia Systems (BSD-2000). The BSD-2000 System utilizes BSD’s proprietary synchronous phased array technology to non-invasively target therapeutic heating (hyperthermia) to certain cancerous tumors, including those located deep within the body. Clinical studies have shown that hyperthermia treatment can kill cancer cells directly as well as increase the effectiveness of other cancer therapies, including radiation therapy, for the treatment of certain tumors.

Hyperthermia cancer therapy has a strong following in China, and Orientech controls about 65% of the market. The Orientech sales force covers 23 provinces. After shipping the two systems, the Company will have sold 19 BSD-2000 Hyperthermia Systems to Orientech. Shares of BSD shot up more than 8% on the news.

Vical Incorporated (Nasdaq:VICL) today announced plans to present final results from the company's Phase 2 trial evaluating the potential for its TransVax(TM) therapeutic DNA vaccine to prevent cytomegalovirus (CMV) reactivation and disease in immunosuppressed hematopoietic cell transplant (HCT) recipients. The company's abstract was accepted for a late-breaker session at the 50th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC, Boston -- September 12-15).

The company will release summary results from the trial before the opening of trading on Tuesday, September 14. Shares rose more than 5% on the news.

Also Thursday:

Anika Therapeutics, Inc. (NASDAQ:ANIK) today announced that Charles Sherwood, president and chief executive officer, will be presenting at the Rodman & Renshaw Annual Global Investment Conference on Wednesday, September 15, 2010 at 9:10 a.m. ET.

Arrowhead Research Corporation (NASDAQ: ARWR) today announced that Dr. Christopher Anzalone, Chief Executive Officer, will be presenting at the Rodman & Renshaw Annual Global Investment Conference at 5:45 p.m. EDT on Tuesday, September 14, 2010, at the Palace Hotel in New York, NY.

AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based therapeutics, today announced upcoming presentations of preclinical data evaluating AVI-7100 against pandemic influenza and AVI-6006 against dengue virus infection at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) taking place September 12-15, 2010 in Boston, Massachusetts.

Biogen Idec Inc. (NASDAQ: BIIB) announced today that its presentation at the Stifel Nicolaus 2010 Healthcare Conference will be webcast live on Wednesday, September, 15, 2010 at 9:10 a.m. EDT.

BioMarin Pharmaceutical Inc. (Nasdaq:BMRN)
today announced that Dan Maher, Senior Vice President of Product Development of BioMarin, will present a company update at the Stifel Nicolaus Healthcare Conference in Boston on Friday, September 17, 2010 at 9:10 a.m. ET.

BioTime, Inc. (NYSE Amex:BTIM)
announced today that its Chief Financial Officer, Steven A. Seinberg, has resigned his position effective September 17, 2010.

CombinatoRx, Incorporated (NASDAQ: CRXX) today announced that it has changed its name to Zalicus Inc. The company will begin trading under the new ticker symbol ZLCS on the NASDAQ Global Market at market open on September 9, 2010.

CVS Caremark (NYSE:CVS) today said that ongoing research into how behavioral economics impacts health care choices found that when consumers are presented with a clear and active choice in a voice-recorded message to select automatic prescription refills, rather than a passive default notification, they are twice as likely to choose the automatic option.

Dehaier Medical Systems, Ltd. (Nasdaq:DHRM) ("Dehaier" or the "Company"), an emerging leader in the development, assembly, marketing, and sale of medical devices and homecare medical products in China, announced today that it has retained RedChip Companies, Inc. to lead its public and investor relations programs.

Geron Corporation (Nasdaq:GERN) today announced that Thomas B. Okarma, Ph.D., M.D., president and chief executive officer, will be presenting at three investor conferences during the month of September. Rodman & Renshaw 12th Annual Healthcare Conference in New York City at 10:25 a.m. ET on Monday, September 13, 2010.

Healthmed Services, Ltd. (OTCBB:HEME), an innovative software development company, is pleased to provide an update on the Company.

Healthzone Limited (ASX:HZL) (OTCQX: HLTZY) (PINKSHEETS: HLTZY), an international leader in the beauty and wellness sector,today announced that the Company will present at the Rodman & Renshaw Annual Global Investment Conference at The Palace Hotel in New York City on September 15, 2010 at 12:30pm Eastern time.

Kevin Murray, President of HIV-VAC, Inc. (PINKSHEETS:HIVV), announced today that the Board of Directors has elected Mr. Ramon Richard as the new President, CEO and a Director of the Company, effective immediately.Mr. Murray will remain a director of the Company, has agreed to act has CFO and will also head the Pharmaceutical Division.

Hop-on, Inc. (PINKSHEETS: HPNN) and USAcig, Inc. support the Food and Drug Administration in the issued warning letters to the following five electronic cigarette manufacturers: E-CigaretteDirect LLC, Ruyan America Inc., Gamucci America (Smokey Bayou Inc.), E-Cig Technology Inc. and Johnson's Creek Enterprises LLC.

Huifeng Bio-Pharmaceutical Technology, Inc. (OTC Bulletin Board:HFGB) specializing in developing and producing botanical extracts and other raw materials for pharmaceuticals and food additives, today announces a definitive agreement under which Huifeng will acquire 90% of the equity ownership of Shangqiu Kexin Rutin Processing Ltd. ("Kexin"), a local leading Rutin manufacturer in Henan Province, at a price of $1.75 million.

Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) will present at the Morgan Stanley Global Healthcare Conference on Tuesday, September 14, 2010 at 1:35 p.m. Eastern Time at the Grand Hyatt New York in New York City.

Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that Dr. Arthur T. Sands, president and chief executive officer, will present at the Stifel Nicolaus Healthcare Conference in Boston on Thursday, September 16, 2010 at 9:10 a.m. Eastern Time.

Molecular Insight Pharmaceuticals, Inc. (NASDAQ:MIPI), a biopharmaceutical company discovering and developing targeted therapeutic and imaging radiopharmaceuticals for use in oncology, today announced that the Company has received a ninth extension of its waiver agreement with its Bond holders, allowing debt restructuring discussions to continue.

Nile Therapeutics, Inc. (Nasdaq:NLTX), a company focused on the development of novel therapeutics for heart failure patients, today announced that Joshua Kazam, Chief Executive Officer, will present at the Rodman & Renshaw 12th Annual Global Investment Conference on Tuesday, September 14, 2010 at 2:00 p.m. (Eastern Time) at the Palace Hotel in New York City, New York.

Ophthalmic Imaging Systems (OIS) (OTCBB: OISI), a leading ophthalmic digital imaging and informatics company, announces that Chief Executive Officer Gil Allon and Chief Financial Officer Ariel Shenhar will present at the Rodman & Renshaw 12th Annual Healthcare Conference on Tuesday, September 14, 2010 at 12:30 p.m. Eastern time (9:30 a.m. Pacific time).

OXIS International, Inc., (OTC Bulletin Board:OXIS;  Paris: OXI) today announced that Anthony Cataldo, chief executive officer, and Bernie Landes, president, are scheduled to make an investor presentation at the Rodman & Renshaw Annual Global Investment Conference on Monday, September 13, 2010 at 3:15 p.m. Eastern time (12:15 p.m. Pacific time).  

PDL BioPharma, Inc. (PDL) (Nasdaq:PDLI) today announced that NASDAQ has established September 13, 2010 as the ex-dividend date for its second of two special dividends to stockholders declared by the Board of Directors on January 27, 2010.

PharmaGap Inc. (TSX VENTURE:GAP) (OTCBB:PHRGF) today reported the granting of 2,000,000 options to Directors and Officers of the Company pursuant to the Company's Employee Stock Option Plan ("ESOP").

pSivida Corp, (NASDAQ:PSDV) (ASX:PSD), a leader in the development of sustained release back of the eye drug delivery systems for difficult-to-treat conditions, today announced that it will webcast a live presentation at the Rodman & Renshaw Annual Health Care Conference in New York, Monday, September 13. Dr. Paul Ashton, President and Chief Executive Officer of pSivida, will present at 2:00 p.m. Eastern time.

Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled to present a company overview at the Stifel Nicolaus Healthcare Conference in Boston, MA on Thursday, September 16th at 9:45a.m. EDT.

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced that the Company will present at the Stifel Nicolaus Healthcare Conference 2010 in Boston, MA on Thursday, September 16 at 2:05 p.m. ET.

Shire plc (LSE: SHP, NASDAQ:SHPGY), the global specialty biopharmaceutical company, today announced the expansion of its Human Genetic Therapies pipeline through the exclusive license, in markets outside of North America, for the activin receptor type IIB (ActRIIB) class of molecules being developed by Acceleron Pharma Inc., a private biotechnology company based in Cambridge, Massachusetts.

Simulations Plus, Inc. (NASDAQ:SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, today announced that Walter S. Woltosz, the Company's chairman of the board, CEO and president, will present at the Rodman & Renshaw Annual Global Investment Conference at 12:05 p.m. (ET) on September 13, 2010.

Stellar Biotechnologies, Inc. (PINKSHEETS:SBOTF) (TSX-V: KLH) announces filing for patent protection of inventions related to its native Immunogenic (IMG) KLH technology platform and immune status monitoring product portfolio.KLH (keyhole limpet hemocyanin) is presently the most pharmaceutically important ICP (immune carrier protein) and IMG KLH is the most effective immune stimulant for use in cancer, viral and parasite vaccines; animal vaccines; and diagnostic products.

Sigma-Aldrich Corporation (Nasdaq:SIAL) will be presenting at the Stifel Nicolaus 2010 Healthcare Conference on Thursday, September 16th at 2:05 PM ET in Boston, MA.

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced that its board of directors has authorized the repurchase of an additional $750 million of shares of its own common stock in the open market or in negotiated transactions.

TomoTherapy Incorporated (NASDAQ: TOMO), maker of advanced, integrated radiation therapy solutions for cancer care, today announced that its technology will soon be used to treat cancer patients in Nottingham, England.

Transdel Pharmaceuticals, Inc. (OTC Bulletin Board:TDLP) reported today that JH Direct has completed their initial product testing of Transdel's anti-cellulite formulation in 24 subjects, which consisted of observing the before and after results of applying the product over a 16 week period.  

WaferGen Biosystems, Inc. (OTC Bulletin Board:WGBS), a leading developer of state-of-the-art genomic analysis systems, today announced that its corporate presentation will be webcast live at Rodman and Renshaw's 12th Annual Global Healthcare Conference, Tuesday, September 14, 2010, beginning at 12:05 p.m. Eastern Time.

West Pharmaceutical Services, Inc. (NYSE:WST) today announced that the company will participate in two upcoming investor conferences.




"Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!

blog comments powered by Disqus
 

Newsletter